Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2- metastatic breast cancer

Future Oncol. 2017 Jul;13(17):1451-1453. doi: 10.2217/fon-2017-0190. Epub 2017 Jul 7.

Authors

Elie El Rassy¹, Pamela Abdayem¹, Joseph Kattan¹

Affiliation

¹ Department of Medical Oncology, Faculty of Medicine, Hotel Dieu de France University Hospital, Saint Joseph University, Lebanon.

PMID: 28685610
DOI: 10.2217/fon-2017-0190

No abstract available

Keywords: CDK4/6 inhibitor; mTOR inhibitors; metastatic breast cancer; second line.

Publication types

Editorial

MeSH terms

Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Clinical Trials as Topic
Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
Cyclin-Dependent Kinase 4 / genetics
Estrogen Receptor alpha / genetics
Female
Humans
Molecular Targeted Therapy / trends*
Neoplasm Metastasis
Receptor, ErbB-2 / genetics
Signal Transduction / drug effects
TOR Serine-Threonine Kinases / antagonists & inhibitors*
TOR Serine-Threonine Kinases / genetics

Substances

ESR1 protein, human
Estrogen Receptor alpha
MTOR protein, human
Receptor, ErbB-2
TOR Serine-Threonine Kinases
CDK4 protein, human
Cyclin-Dependent Kinase 4